Survival in Unresectable Hepatocellular Carcinoma Treated With a New Immune Checkpoint and Anti-angiogenic Drug Combination

Qin S, Chan SL, Gu S, et al. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomized, open-label, international phase 3 study. Lancet. Published online July 24, 2023. https://doi.org/10.1016/S0140-6736(23)00961-3